Thomas Smart
Vorstandsvorsitzender bei Actym Therapeutics, Inc.
Profil
Thomas E.
Smart is the founder of Gravitas Therapeutics, Inc. He currently holds the position of Chief Executive Officer at Actym Therapeutics, Inc. since 2024.
He is also a Director at RIGImmune, Inc. and Vice President-Business Development at XOMA (US) LLC.
Previously, he served as Co-Chairman & Chief Executive Officer at AnaptysBio, Inc. in 2011.
He has also worked as a Director at Acologix, Inc., Principal at Cell Genesys, Inc., Principal at Genetics Institute LLC, Principal at Pfizer Inc., Senior Vice President-Corporate Development at GenVec, Inc., and Chief Business Officer at XOMA Corp.
Mr. Smart obtained an MBA from The University of Chicago and an undergraduate degree from Cornell University.
He also holds an MBA from The University of Chicago Booth School of Business.
Aktive Positionen von Thomas Smart
| Unternehmen | Position | Beginn |
|---|---|---|
XOMA (US) LLC
 XOMA (US) LLC Pharmaceuticals: MajorHealth Technology XOMA (US) LLC develops pharmaceutical preparations. It offers proprietary drugs and toiletries. The company is headquartered in Emeryville, CA. | Corporate Officer/Principal | - |
RIGImmune, Inc.
 RIGImmune, Inc. Miscellaneous Commercial ServicesCommercial Services RIGImmune, Inc. is a platform biopharmaceutical company based in Farmington, CT, with subsidiaries in the United Kingdom. The company is developing a novel investigational class of RNA immunotherapies called "SLRs" for the potential pan-viral treatment and prophylaxis of viral respiratory diseases and selected cancers. The lead development candidate at RIGImmune is RIG-101, which specifically modulates RIG-I, a host surveillance pathway that triggers the innate immune system to enhance an intrinsic response to RNA viruses, including influenza, RSV, rhinovirus, and SARS-CoV-2, and tumor DNA. The company was founded in 2020 by Akiko Iwasaki and Anna Marie Pyle, both prominent Yale University professors who currently serve as scientific advisors to the company. | Direktor/Vorstandsmitglied | - |
Actym Therapeutics, Inc.
 Actym Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Actym Therapeutics, Inc. engages in development of novel immuno-oncology therapies. The company was founded by Christopher D. Thanos and Laura Hix Glickman and is headquartered in Berkeley, CA. | Vorstandsvorsitzender | 24.04.2024 |
Ehemalige bekannte Positionen von Thomas Smart
| Unternehmen | Position | Ende |
|---|---|---|
Gravitas Therapeutics, Inc.
 Gravitas Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Gravitas Therapeutics, Inc. is an American clinical-stage company that provides antifungal treatment for aspergillus mold infections. The CEO of the private company is Thomas E. Smart. | Vorstandsvorsitzender | 01.10.2023 |
| XOMA CORPORATION | Corporate Officer/Principal | - |
| PFIZER, INC. | Corporate Officer/Principal | - |
Genetics Institute LLC
 Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Corporate Officer/Principal | - |
Ausbildung von Thomas Smart
| Cornell University | Undergraduate Degree |
| The University of Chicago Booth School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| PFIZER, INC. | Health Technology |
| XOMA CORPORATION | Health Technology |
| ANAPTYSBIO, INC. | Health Technology |
| Private Unternehmen | 8 |
|---|---|
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
Genetics Institute LLC
Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Health Technology |
GenVec, Inc.
 GenVec, Inc. Pharmaceuticals: MajorHealth Technology GenVec, Inc. operated as a clinical-stage gene delivery company, which engaged in the development of therapeutics and vaccines. The firm designs, tests, and manufactured adenoviral-based product candidates using its proprietary AdenoVerse platform. Its products included CGF166-Hearing Loss; GV2311-RSV Vaccine; and GV2207-HSV-2 Immunotherapeutic. The company was founded in December 1992 and was headquartered in Rockville, MD. | Health Technology |
Acologix, Inc.
 Acologix, Inc. Pharmaceuticals: MajorHealth Technology Acologix, Inc. develops and commercializes medicines. The company was founded by Yoshinari Kumagai in 1992 and is headquartered in Hayward, CA. | Health Technology |
XOMA (US) LLC
XOMA (US) LLC Pharmaceuticals: MajorHealth Technology XOMA (US) LLC develops pharmaceutical preparations. It offers proprietary drugs and toiletries. The company is headquartered in Emeryville, CA. | Health Technology |
Actym Therapeutics, Inc.
Actym Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Actym Therapeutics, Inc. engages in development of novel immuno-oncology therapies. The company was founded by Christopher D. Thanos and Laura Hix Glickman and is headquartered in Berkeley, CA. | Health Technology |
RIGImmune, Inc.
RIGImmune, Inc. Miscellaneous Commercial ServicesCommercial Services RIGImmune, Inc. is a platform biopharmaceutical company based in Farmington, CT, with subsidiaries in the United Kingdom. The company is developing a novel investigational class of RNA immunotherapies called "SLRs" for the potential pan-viral treatment and prophylaxis of viral respiratory diseases and selected cancers. The lead development candidate at RIGImmune is RIG-101, which specifically modulates RIG-I, a host surveillance pathway that triggers the innate immune system to enhance an intrinsic response to RNA viruses, including influenza, RSV, rhinovirus, and SARS-CoV-2, and tumor DNA. The company was founded in 2020 by Akiko Iwasaki and Anna Marie Pyle, both prominent Yale University professors who currently serve as scientific advisors to the company. | Commercial Services |
Gravitas Therapeutics, Inc.
Gravitas Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Gravitas Therapeutics, Inc. is an American clinical-stage company that provides antifungal treatment for aspergillus mold infections. The CEO of the private company is Thomas E. Smart. | Commercial Services |
